Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lexaria Bioscience Q3 EPS $(0.21) Misses $(0.16) Estimate, Sales $174.000K Beat $91.333K Estimate

Author: Benzinga Newsdesk | July 14, 2025 06:32pm
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.16) by 33.76 percent. This is a 61.54 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $174.000 thousand which beat the analyst consensus estimate of $91.333 thousand by 90.51 percent. This is a 107.14 percent increase over sales of $84.000 thousand the same period last year.

Posted In: LEXX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist